2020年11月30日星期一
 
專家論市
Martin Hennecke

Drug firm cautions after stock surges
 
19/10/2020
 
<p>Guangzhou Baiyunshan Pharmaceutical (0874), whose stock surged the most in two years last Friday on reports one of its medicines could potentially inhibit Covid-19, said more studies are needed on the treatment.</p><p>Shares of Baiyunshan climbed 13 percent in Hong Kong and by the 10 percent limit in Shanghai last Friday after Zhong Nanshan, one of the nation&#39;s top medical advisers, reportedly said one of its treatments could potentially inhibit Covid-19. .</p><p>Zhong will lead a team working on the development and upgrades of the drug, according to the Nanfang Daily.</p><p>More work needs to be done in studies of banlangen and sales of the medicine are not expected to have a major impact on Baiyunshan&#39;s performance, it said in a statement to the Shanghai stock exchange, where it&#39;s listed.</p><p>Banlangen is a traditional Chinese medicine made from isatis root and often used as a common cure for cold and flu.</p>
上一篇新聞 : JD Health aiming for $27b
 

 

 
登入名稱
密碼
新用戶注冊   忘記密碼
進階搜尋
© 2020 The Standard, The Standard Newspapers Publishing Ltd.
Home | Business | Metro | Focus | Opinion | Markets | World | Sports | Entertainment | Monday Money | Property | Macau | Weekend